Arcturus Therapeutics
Arcturus Therapeutics' revenue fell 46.1% to $82 million in fiscal 2025. Its operating margin was −93.0%, down from −62.8% a year earlier. Free cash flow was −$74 million. The diluted share count rose 1.4%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Arcturus Therapeutics does
Arcturus Therapeutics develops medicines and vaccines based on messenger RNA (mRNA), the molecule that tells cells how to make a protein. It focuses on rare diseases of the liver and lungs, and it also has vaccines for infectious diseases. It uses its own technologies: STARR, a self-amplifying mRNA platform, and LUNAR, a fat-based particle system that delivers RNA to the target tissue.
Its internal programs are in Phase 2 trials for ornithine transcarbamylase (OTC) deficiency, a rare liver disorder, and for cystic fibrosis. It developed KOSTAIVE, a self-amplifying mRNA COVID-19 vaccine approved in Japan, the European Union and the United Kingdom. It sells the vaccine through its partner CSL Seqirus, part of CSL Limited, and sales began in Japan in October 2024.
CSL Seqirus also works with Arcturus on mRNA vaccines for influenza and three other infectious diseases. The 10-K notes that CSL reported an accounting write-down on this collaboration in February 2026, citing declining COVID-19 disease burden and tougher U.S. regulatory requirements.
Its biggest risks, as it describes them
- A history of significant losses, and a need to raise more capital that may not be available.
- It depends heavily on its relationship with CSL Seqirus for its vaccines.
- It relies on collaboration partners, whose relationships could fail.
- It relies on contract makers and research organizations to produce and test its candidates.
Income statement
Arcturus Therapeutics lost money in fiscal 2025: a net loss of $66 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 370 | 392 | 292 | 237 | 231 |
| Debt incl. finance leases | 15 | — | — | — | — |
| Net debt (negative means net cash) | −355 | — | — | — | — |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | 0.1x | — | — | — | — |
| Interest coverage | −296.6x | 15.0x | −36.8x | — | — |
| Current ratio | 3.8x | 3.2x | 4.7x | 4.7x | 6.6x |
| Quick ratio | 3.8x | 3.2x | 4.7x | 4.7x | 6.6x |
Cash flow
Projections
Project Arcturus Therapeutics' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
No officer, director or 10% owner of Arcturus Therapeutics reported buying or selling its shares on the open market between November 20, 2025 and November 19, 2026.
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | — | — |
| Rule of 40 | −31.6% | −48.3% | −137.0% |
| Altman Z'' | 2.57 | 0.92 | 0.81 |
| Accruals ratio | −2.6% | −5.5% | 2.8% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Fail | Fail | Fail |
| Cash from operations exceeds net income | Pass | Pass | Fail |
| Debt fell relative to assets | — | — | — |
| Current ratio rose | Pass | Fail | Pass |
| Share count didn't rise | Pass | Fail | Fail |
| Gross margin rose | — | — | — |
| Revenue rose relative to assets | Fail | Fail | Fail |
| F-score | — | — | — |
Compare
Put Arcturus Therapeutics side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Arcturus Therapeutics | FY25 | −46.1% | −93.0% | −90.8% | — | — | — | |
| Nurix Therapeutics | FY25 | 54.0% | −340.2% | −313.7% | — | — | — | Compare |
| Eton Pharmaceuticals | FY25 | 104.9% | −1.1% | 12.8% | −1.9% | 1.4x | 4 | Compare |
| ARS Pharmaceuticals | FY25 | −5.5% | −212.9% | −203.1% | — | — | 2 | Compare |
| Assembly Biosciences | FY25 | 153.5% | −16.8% | −56.9% | — | — | — | Compare |
8 years of figures
| Fiscal year | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | 16 | 21 | 10 | 12 | 206 | 167 | 152 | 82 |
| Revenue growth | — | 32.0% | −54.1% | 29.6% | 1,566.8% | −19.0% | −8.7% | −46.1% |
| Gross profit | — | — | — | — | — | — | — | — |
| Research and development | 17 | 34 | 58 | 174 | 148 | 192 | 195 | 112 |
| Operating income | −22 | −26 | −72 | −203 | 12 | −78 | −96 | −76 |
| Net income | −22 | −26 | −72 | −204 | 9 | −30 | −81 | −66 |
| Diluted EPS (US$) | −2.16 | −2.15 | −3.55 | −7.74 | 0.35 | −1.12 | −3.00 | −2.40 |
| Diluted shares (millions) | 10 | 12 | 20 | 26 | 27 | 27 | 27 | 27 |
| Cash flow | ||||||||
| Cash from operations | −21 | −6 | −43 | −135 | 32 | −18 | −60 | −74 |
| Capital expenditure | 2 | 1 | 2 | 3 | 8 | 3 | 1 | 0 |
| Free cash flow | −22 | −7 | −45 | −138 | 24 | −21 | −60 | −74 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 1 | 2 | 7 | 29 | 31 | 35 | 38 | 25 |
| Balance sheet at fiscal year end | ||||||||
| Cash and short-term investments | 37 | 71 | 463 | 370 | 392 | 292 | 237 | 231 |
| Debt incl. finance leases | 10 | 15 | 15 | 15 | — | — | — | — |
| Total assets | 44 | 82 | 476 | 393 | 450 | 429 | 344 | 271 |
| Total liabilities | 31 | 56 | 80 | 165 | 180 | 151 | 103 | 57 |
| Shareholders' equity | 14 | 26 | 397 | 228 | 270 | 278 | 241 | 214 |
| Margins and ratios | ||||||||
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | −138.5% | −122.7% | −749.8% | −1,641.3% | 5.9% | −46.9% | −62.8% | −93.0% |
| Net margin | −138.3% | −125.0% | −756.4% | −1,648.0% | 4.5% | −17.8% | −53.1% | −80.2% |
| Free cash flow margin | −141.2% | −34.9% | −467.6% | −1,120.2% | 11.8% | −12.6% | −39.6% | −90.8% |
| Rule of 40 (growth + FCF margin) | — | −3.0% | −521.7% | −1,090.7% | 1,578.6% | −31.6% | −48.3% | −137.0% |
| Return on capital | — | — | — | — | — | — | — | — |
| Return on equity | — | −131.8% | −34.2% | −65.2% | 3.8% | −10.8% | −31.2% | −28.9% |
| Return on assets | — | −41.1% | −25.8% | −46.9% | 2.2% | −6.8% | −20.9% | −21.4% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — |